Brian W. Nolan is a Partner at Mayer Brown and a member of the Intellectual Property group. Brian focuses his practice on intellectual property litigation, licensing, counseling, and due diligence in the areas of patent, trade secret, unfair competition, antitrust, trademark, counterfeit goods, and copyright law. Brian has handled matters in all types of technology and moves seamlessly from life sciences to high tech to consumer goods matters. Throughout his career Brian has received various recognitions. Chambers quotes clients saying that “he understands a client’s needs and applies it to the business issue at hand very effectively.” LMG Life Sciences recognized Brian as a “Life Sciences Star,” and according to IAM 1000 “Brian takes a very pragmatic approach and completely understands the business side of things; he has also committed to memory all the case precedents for the most frequently litigated pharmaceutical patent issues. Furthermore, he’s the most responsive outside counsel you could hope to work with and is highly effective at managing projects within budget constraints” and “is a key asset to the firm, given his wealth of pharmaceutical and biotechnology litigation expertise and ability to cross over seamlessly into other fields such as semiconductors and information technology.”
Brian has acted as lead trial counsel and appellate counsel on numerous matters covering all aspects of intellectual property protection. Brian has participated in several district court trials, ITC investigations, USPTO Inter Partes Review and appellate proceedings relating to a wide range of technologies, including monoclonal antibodies, pharmaceuticals, receptor pharmacology, medical devices, biotechnology, medical imaging technology, crystal growth, semiconductors, laser diodes, building products, data capture systems and computer storage systems. Brian has experience counseling clients concerning their biological products, including working to develop strategies to allow for introduction of new biologics to the marketplace and seeking to protect existing biologics from potential biosimilars competition. Additionally, Brian has experience litigating cases brought under the Hatch-Waxman statute and counseling innovator pharmaceutical companies regarding their patent portfolios and potential generic competition prior to patent expiry.
Brian regularly assists in business transactions in which IP assets and artificial intelligence form a key component of the value. Brian often advises on M&A, capital markets and other corporate transactions, including joint ventures, collaborations, licensing, private equity, venture capital, and hedge fund transactions. Brian counsels investment companies concerning acquisitions in which the buyer’s valuation is driven by IP assets. He works with public and private companies to develop patent strategies to enhance overall value.
Brian has acted as an adjunct professor of law at Fordham University School of Law, where he taught a course on patent litigation for many years. Brian speaks and writes on intellectual property issues at many events and in various publications. News organizations often seek Brian’s views on current intellectual property issues.
Check back soon for more articles by Brian W. Nolan